FOx Biosystems
Open bankruptcyDirectors
Directors
7 directors, 1 in day-to-day management, last change in 2024
Board 7
Mark Truesdale
CurrentBestuurder én persoon belast met het dagelijks bestuur · since 01-09-2023
Jerry Williamson
CurrentIndependent director · since 01-01-2024
Bart Geers
CurrentDirector · since 29-01-2024
Filip Delport
CurrentDirector · since 29-01-2024
Heran Partners
CurrentDirector · since 29-01-2024 · Legal entity · permanent representative: Katleen Vandersmissen
Jeroen Lammertyn
CurrentDirector · since 29-01-2024
LRM Beheer
CurrentDirector · since 29-01-2024 · Public limited company · permanent representative: Dries Bauters
Day-to-day management 1
Mark Truesdale
CurrentBestuurder én persoon belast met het dagelijks bestuur · since 01-09-2023
Permanent representatives 2
Dries Bauters
CurrentPermanent representative · since 29-01-2024 · for LRM Beheer
Katleen Vandersmissen
CurrentPermanent representative · since 29-01-2024 · for Heran Partners
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ.
See the directors and other office holders in the KBO →
Not every act has been read: a resignation may still be missing
13 of this company's 17 Belgian Official Gazette deeds have not been read yet. Appointments and resignations recorded in them are not yet in the list of directors: someone who resigned there may still be listed as sitting. The acts are in the Timeline.
Mandate history
8 people since 2023, 7 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Mark Truesdale |
|
| Jerry Williamson |
|
| Bart Geers |
|
| Filip Delport |
|
| Heran Partners |
|
| Jeroen Lammertyn |
|
| LRM Beheer |
|
| Vithea BV |
|
Insolvency mandates
3 mandates| Role | Name | Tenure |
|---|---|---|
| Trustee | Geert Reniers Jaarbeurslaan 19/31, 3600 Genk |
23-01-2025 → present |
| Trustee | Tom Arts Jaarbeurslaan 19/31, 3600 Genk |
23-01-2025 → present |
| Trustee | Ilona Lo Giudice Jaarbeurs- Laan 19/31, 3600 Genk |
23-01-2025 → present |
Owners and capital
Owners
7 ownersOwners 7
-
33.94%
-
30.6%
- Leuven KUnatural personSourceown accounts 202214.15%
- Filip Delportnatural personSourceown accounts 202213.11%
- Jeroen Lammertynnatural personSourceown accounts 20227.82%
- Gemma Frisius Fondsnatural personSourceown accounts 20226.69%
- Cetromed LtdGBSourceown accounts 20224.29%
According to the 2023 annual accounts of FOx Biosystems and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
Shareholders according to the deeds
After the capital increase
act of 09-08-2024 ↗
- Limburgse Reconversie Maatschappij 3,846 shares · €290,410.31
- Heran Healthtech Fund I 3,846 shares · €290,410.31
- Katholieke Universiteit Leuven 1,470 shares · €110,999.26
- Gemma Frisius-Fonds KU Leuven 637 shares · €48,099.68
After 4 capital increases
act of 13-05-2024 ↗
- NV Limburgse Reconversie Maatschappij 5,769 shares · schuldvordering
- KU Leuven 711 shares · €53,687.40 · schuldvordering
- CommV Heran Healthtech Fund I 5,769 shares · schuldvordering
- Katholieke Universiteit Leuven 2,986 shares · in cash
- NV Gemma Frisius-Fonds KU Leuven 1,910 shares · in cash
- TrueLife Science Consulting Limited 794 shares · €59,954.70 in cash
- BV Confluence Consulting 331 shares · €24,993.71 in cash
- BV L.E.A.F. Management 463 shares · €34,960.99 in cash
- BioBiz Ltd 331 shares · €24,993.71 in cash
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
Capital over the years
- 09-08-2024 Capital increase · to €1,518,265.05 · 9,799 new shares · in cash
- 13-05-2024 Capital increase of €249,861.60 · to €1,219,041.44 · 3,309 new shares · in kind
- 13-05-2024 Capital increase of €859,904.46 · to €1,298,301.60 · 11,388 new shares
- 13-05-2024 Capital increase of €144,903.11 · to €1,443,204.71 · 1,919 new shares